All In Biotech

Drug Trial Radar · NCT06934382

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

A Phase 1 Study of Allogeneic Anti-CD7 CAR-T Cells (BEAM-201) in Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) or T-cell Lymphoblastic Lymphoma (T-LLy)

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

33

Planned (sponsor's estimate)

Start

Apr 29, 2025

Primary completion

May 30, 2029

Study completion May 30, 2031

Sponsor

Lead sponsor
Stephan Grupp MD PhDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Beam Therapeutics Inc.
First posted
Apr 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 years, up to 29 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogeneic anti-CD7 CART therapy.

Conditions

  • T-Cell Acute Lymphoblastic Leukemia/Lymphoma

Interventions

  • Allogeneic anti-CD7 CAR-T cells (BEAM-201)Biological

    The investigational agent in this protocol is allogeneic anti-CD7 CART cells (BEAM-201). BEAM-201 is comprised of allogeneic anti-CD7 CAR-T cells edited by 4 gRNAs and a single mRNA encoding a CBE, then transduced with a lentiviral vector (LVV) encoding the anti-CD7 chimeric antigen receptor (CAR) molecule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the Maximum Tolerate Dose of Beam 201 CellsTime frame: 5 years
  2. Frequency of Adverse Events Following Beam-201 administrationTime frame: 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.